课题基金 / 基金详情

STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides

STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
STAT3、G6PD 和 TrxR 作为毛毛素内酯类抗肿瘤反应的潜在机制
批准号:
10005721
负责人:
James K Turkson
金额:
$26.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2022-02-28

项目摘要

项目成果

James K Turkson的其他基金

相似基金

相关文献

中文摘要
翻译
多形性胶质母细胞瘤(GBM)和乳腺癌是主要的健康负担,将受益于新的
英文摘要
Glioblastoma multiforme (GBM) and breast cancer are major health burdens that will benefit from new mechanistic insights that lead to novel management strategies. We propose to investigate Signal Transducer and Activator of Transcription (STAT)3, thioredoxin reductase (TrxR)1 cytoplasmic isoform 3, and glucose-6-phosphate 1-dehydrogenase (G6PD) isoform a as the targeting mechanisms underlying the antitumor responses of GBM and triple-negative breast cancer to hirsutinolide compounds. The hirsutinolide series are the major chemical constituents of Vernonia cinerea. This plant has traditionally been used in Asia to treat specific ailments and in clinical trials proofed to be effective to moderate type 2 diabetes and curtail smoking. Despite the therapeutic potential of the hirsutinolides, however, little was known of their pharmacological properties to facilitate their clinical development until our studies. Our compelling data show that structurally suitable hirsutinolides strongly inhibit STAT3, TrxR1 and G6PD functions and thereby suppress breast cancer and GBM phenotypes in vitro and in vivo. Initial structure activity relationship analysis showed a critical requirement for a position 13 ester group for the activities. Unbiased computational modeling/docking and nuclear magnetic resonance structural studies show that structurally suitable hirsutinolides bind the STAT3 DNA-binding domain (DBD) via hydrophobic interactions between the position 13 side chain and specific amino acid residues in the STAT3 DBD. Select compounds caused mitotic and cell cycle arrests and inhibited growth of human breast cancer and GBM xenografts. In line with the TrxR1 or G6PD functional roles in the cellular protection against the oxidative damage from excessive reactive oxygen species (ROS) or in the pentose phosphate pathway for NADPH production, respectively, ROS levels and glycolytic metabolites, including glucose, G6P and pyruvate are significantly altered in hirsutinolide-treated tumor cells. We hypothesize that structurally suitable hirsutinolides are inherently active against STAT3, TrxR1 and G6PD functions, and alter cellular redox events and glycolytic metabolism, and thereby block breast cancer and GBM progression. We will determine the SAR of the hirsutinolides relative to inhibition of STAT3 activity and elucidate the structural determinants for STAT3 inhibition (Aim 1), investigate the mechanistic details of the STAT3 signaling inhibition by hirsutinolides and the significance to the antitumor responses against GBM and breast cancer (Aim 2), define the mechanistic link between STAT3, TrxR1 and G6PD functions, altered cellular redox recycle, metabolism, mitosis and cell cycle (Aim 3), and study the antitumor efficacy responses of select hirsutinolide analogs and their correlation to STAT3, TrxR1 and G6PD-dependent molecular and metabolomic events in vivo (Aim 4). Data will ultimately facilitate the development of the hirsutinolides as potential therapeutics for breast cancer and GBM.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
11th Annual Meeting of International Cytokine & Interferon Society
  • 批准号:
    10753947
  • 项目类别:
  • 资助金额:
    $0.5万
  • 财政年份:
    2023
  • 负责人:
    James K Turkson
  • 依托单位:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses to hirsutinolides
  • 批准号:
    9443606
  • 项目类别:
  • 资助金额:
    $50.27万
  • 财政年份:
    2017
  • 负责人:
    James K Turkson
  • 依托单位:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
  • 批准号:
    10098001
  • 项目类别:
  • 资助金额:
    $54.99万
  • 财政年份:
    2017
  • 负责人:
    James K Turkson
  • 依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
  • 批准号:
    8370490
  • 项目类别:
  • 资助金额:
    $48.94万
  • 财政年份:
    2012
  • 负责人:
    James K Turkson
  • 依托单位:
国内基金
海外基金
UDCA抑制G6PD活性诱导 HCC 细胞铁死亡的抗肝癌机制研究
  • 批准号:
    2026JJ82280
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    熊玉婕
  • 依托单位:
HCP5调控G6PD泛素化降解介导肺腺癌奥希替尼耐药的作用及机制研究
  • 批准号:
    2026JJ81745
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    王子尧
  • 依托单位:
G6PD通过SYK/JNK通路调节破骨分化缓解绝经后骨质疏松症的作用机制
  • 批准号:
    --
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    彭志
  • 依托单位:
DDX27 通过双重调控 G6PD抑制铁死亡而促进结直肠癌 增殖及耐药的机制
  • 批准号:
    2024JJ6663
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    伍至维
  • 依托单位: